114 related articles for article (PubMed ID: 12500855)
1. Global gene expression changes during neoadjuvant chemotherapy for human breast cancer.
Buchholz TA; Stivers DN; Stec J; Ayers M; Clark E; Bolt A; Sahin AA; Symmans WF; Hess KR; Kuerer HM; Valero V; Hortobagyi GN; Pusztai L
Cancer J; 2002; 8(6):461-8. PubMed ID: 12500855
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin, and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures.
Rody A; Karn T; Gätje R; Kourtis K; Minckwitz G; Loibl S; Munnes M; Ruckhäberle E; Holtrich U; Kaufmann M; Ahr A
Zentralbl Gynakol; 2006 Apr; 128(2):76-81. PubMed ID: 16673249
[TBL] [Abstract][Full Text] [Related]
3. Immediate gene expression changes after the first course of neoadjuvant chemotherapy in patients with primary breast cancer disease.
Modlich O; Prisack HB; Munnes M; Audretsch W; Bojar H
Clin Cancer Res; 2004 Oct; 10(19):6418-31. PubMed ID: 15475428
[TBL] [Abstract][Full Text] [Related]
4. Gene expression pathway analysis to predict response to neoadjuvant docetaxel and capecitabine for breast cancer.
Korde LA; Lusa L; McShane L; Lebowitz PF; Lukes L; Camphausen K; Parker JS; Swain SM; Hunter K; Zujewski JA
Breast Cancer Res Treat; 2010 Feb; 119(3):685-99. PubMed ID: 20012355
[TBL] [Abstract][Full Text] [Related]
5. Deletions of multidrug resistance gene loci in breast cancer leads to the down-regulation of its expression and predict tumor response to neoadjuvant chemotherapy.
Litviakov NV; Cherdyntseva NV; Tsyganov MM; Slonimskaya EM; Ibragimova MK; Kazantseva PV; Kzhyshkowska J; Choinzonov EL
Oncotarget; 2016 Feb; 7(7):7829-41. PubMed ID: 26799285
[TBL] [Abstract][Full Text] [Related]
6. Total RNA yield and microarray gene expression profiles from fine-needle aspiration biopsy and core-needle biopsy samples of breast carcinoma.
Symmans WF; Ayers M; Clark EA; Stec J; Hess KR; Sneige N; Buchholz TA; Krishnamurthy S; Ibrahim NK; Buzdar AU; Theriault RL; Rosales MF; Thomas ES; Gwyn KM; Green MC; Syed AR; Hortobagyi GN; Pusztai L
Cancer; 2003 Jun; 97(12):2960-71. PubMed ID: 12784330
[TBL] [Abstract][Full Text] [Related]
7. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer.
Sotiriou C; Powles TJ; Dowsett M; Jazaeri AA; Feldman AL; Assersohn L; Gadisetti C; Libutti SK; Liu ET
Breast Cancer Res; 2002; 4(3):R3. PubMed ID: 12052255
[TBL] [Abstract][Full Text] [Related]
8. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer.
Hannemann J; Oosterkamp HM; Bosch CA; Velds A; Wessels LF; Loo C; Rutgers EJ; Rodenhuis S; van de Vijver MJ
J Clin Oncol; 2005 May; 23(15):3331-42. PubMed ID: 15908647
[TBL] [Abstract][Full Text] [Related]
9. Response to Preoperative Radiation Therapy in Relation to Gene Expression Patterns in Breast Cancer Patients.
Bosma SCJ; Hoogstraat M; van der Leij F; de Maaker M; Wesseling J; Lips E; Loo CE; Rutgers EJ; Elkhuizen PHM; Bartelink H; van de Vijver MJ
Int J Radiat Oncol Biol Phys; 2020 Jan; 106(1):174-181. PubMed ID: 31525407
[TBL] [Abstract][Full Text] [Related]
10. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients.
Park S; Shimizu C; Shimoyama T; Takeda M; Ando M; Kohno T; Katsumata N; Kang YK; Nishio K; Fujiwara Y
Breast Cancer Res Treat; 2006 Sep; 99(1):9-17. PubMed ID: 16752223
[TBL] [Abstract][Full Text] [Related]
11. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
12. Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas.
López-Knowles E; Gao Q; Cheang MC; Morden J; Parker J; Martin LA; Pinhel I; McNeill F; Hills M; Detre S; Afentakis M; Zabaglo L; Dodson A; Skene A; Holcombe C; Robertson J; Smith I; Bliss JM; Dowsett M;
Breast Cancer Res; 2016 Apr; 18(1):39. PubMed ID: 27036195
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer.
Folgueira MA; Carraro DM; Brentani H; Patrão DF; Barbosa EM; Netto MM; Caldeira JR; Katayama ML; Soares FA; Oliveira CT; Reis LF; Kaiano JH; Camargo LP; Vêncio RZ; Snitcovsky IM; Makdissi FB; e Silva PJ; Góes JC; Brentani MM
Clin Cancer Res; 2005 Oct; 11(20):7434-43. PubMed ID: 16243817
[TBL] [Abstract][Full Text] [Related]
14. Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements.
Carter SL; Eklund AC; Mecham BH; Kohane IS; Szallasi Z
BMC Bioinformatics; 2005 Apr; 6():107. PubMed ID: 15850491
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy.
Koike Folgueira MA; Brentani H; Carraro DM; De Camargo Barros Filho M; Hirata Katayama ML; Santana de Abreu AP; Mantovani Barbosa E; De Oliveira CT; Patrão DF; Mota LD; Netto MM; Caldeira JR; Brentani MM
Oncol Rep; 2009 Oct; 22(4):805-13. PubMed ID: 19724859
[TBL] [Abstract][Full Text] [Related]
16. PPAR signaling pathway may be an important predictor of breast cancer response to neoadjuvant chemotherapy.
Chen YZ; Xue JY; Chen CM; Yang BL; Xu QH; Wu F; Liu F; Ye X; Meng X; Liu GY; Shen ZZ; Shao ZM; Wu J
Cancer Chemother Pharmacol; 2012 Nov; 70(5):637-44. PubMed ID: 22903535
[TBL] [Abstract][Full Text] [Related]
17. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole.
Miller WR; Larionov A; Renshaw L; Anderson TJ; Walker JR; Krause A; Sing T; Evans DB; Dixon JM
J Clin Oncol; 2009 Mar; 27(9):1382-7. PubMed ID: 19224856
[TBL] [Abstract][Full Text] [Related]
18. Basal-like molecular subtype and HER4 up-regulation and response to neoadjuvant chemotherapy in breast cancer.
Stickeler E; Pils D; Klar M; Orlowsk-Volk M; Zur Hausen A; Jäger M; Watermann D; Gitsch G; Zeillinger R; Tempfer CB
Oncol Rep; 2011 Oct; 26(4):1037-45. PubMed ID: 21769435
[TBL] [Abstract][Full Text] [Related]
19. Integrated gene expression profile predicts prognosis of breast cancer patients.
Li LF; Xu XJ; Zhao Y; Liu ZB; Shen ZZ; Jin WR; Shao ZM
Breast Cancer Res Treat; 2009 Jan; 113(2):231-7. PubMed ID: 18278552
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer.
Sabine VS; Sims AH; Macaskill EJ; Renshaw L; Thomas JS; Dixon JM; Bartlett JM
Breast Cancer Res Treat; 2010 Jul; 122(2):419-28. PubMed ID: 20480226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
